Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Announcement of UDC Patent Approval (Japan)
FY2025 Q2 Financial Results (Material)
HEALIOS, First Half Net Income Loss Widens, Apr-Jun Net Income Loss Widens
Academic Paper on eNK Cells in "Stem Cell Research and Therapy" -Human iPSC-derived NK cells armed with the six transgenes-
Selection for“Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities” by METI
Healios to Present at the 2025 Jefferies Global Healthcare Conference
FY2025 Q1 Financial Results (Material)
HEALIOS, Jan-Mar (1Q) Net Income Loss Widens
FY2025 Q1 Financial Results (Material)
FY2025 Q1 Financial Results (Material)
FY2025 Q1 Financial Results (Material)
Decision Regarding Policy to File for Conditional and Time-Limited Approval of Ischemic Stroke Treatment in Japan and Development Strategy Overview
Completion of Formal Regulatory Consultation for ARDS and Agreement on the Global Phase 3 Trial (REVIVE-ARDS Study)
Selection for NEDO Public Call Project: 'Verification and Validation of Safety Toward Social Implementation of Japanese Medical-Specialized LLM'
Notice of Upcoming R&D Briefing on ARDS
Sarah Busch, PhD, appointed as CSO of Healios NA, Inc.
Announcement of Changes in Management
ONE-BRIDGE Trial in ARDS - Peer-Reviewed Publication in Japan
Notice of the Partial Amendments to Articles of Incorporation
Notice of the Nomination of Candidates for the HEALIOS K.K. Board of Directors